We Resolve Legal Matters
How can we assist you?
Blogs
More-
Front-Running in Korean Stocks: Where Does It Become Illegal? (A Complete Guide for Foreign Investors, Listed Company Executives, and Finance Professionals in Korea)
If you've been investing in Korean stocks, or working in Korea's financial industry, you've probably heard the term "front-running" (선행매매) come up more and more lately. It's not just an issue for stock YouTubers or chat-room operators. Listed company executives, fund managers, analysts, and even ordinary retail investors can find themselves caught up in it — whether as victims or, in some cases, unwitting participants. The Financial Supervisory Service (FSS) recently identified illegal activity across five YouTube channels and announced it would refer cases to prosecutors. The message is clear: the era of looking the other way is over. Here's what you need to know. 1. What Is Front-Running, Exactly? Front-running means trading on information that isn't yet public — getting in before everyone else does, and profiting when the news breaks. In the Korean market, it typically shows up in three ways. The first is the stock influencer model. A YouTuber or paid trading-room operator quietly buys shares in a stock, then recommends it publicly to subscribers. Once the price jumps, they sell. Subscribers who bought on the recommendation are left holding losses. The second is the corporate insider model. An executive or employee of a listed company learns about positive news — strong earnings, a major contract, an M&A deal — before it's disclosed, and buys shares in advance. Selling before bad news goes public to avoid losses falls into the same category. The third is the financial professional model. An analyst, fund manager, or trader uses advance knowledge of large institutional orders, upcoming research reports, or trading strategies to place personal trades ahead of the market. Under Korea's Financial Investment Services and Capital Markets Act (FSCMA), all three can constitute illegal use of material non-public information, market manipulation, or fraudulent trading — carrying criminal penalties, fines, and disgorgement of profits. 2. What Does "Illegal" Actually Mean Here? Regulators look at three things together: the nature of the information (was it material and non-public?), the person's relationship to that information (did they have it through their job or position?), and the timing of the trade. Critically, it doesn't matter whether the trade was ultimately profitable. Using the information to trade — full stop — is the issue. Some specific situations that have drawn enforcement action in Korea include paid subscription services where operators recommended stocks they already owned, auto-trading bots sold without the required investment discretionary license, and YouTube channels providing ongoing investment advice without registering as an investment advisory business (유사투자자문업). One thing worth noting for foreign investors: Korean regulators have been actively cooperating with overseas financial authorities. Cross-border cases are no longer treated as out of reach. 3. If You're a Retail Investor: Protect Yourself The two risks individual investors face are being victimized and, less obviously, being mistaken for a participant. Paid trading rooms (리딩방) on KakaoTalk, Telegram, or Discord can look legitimate on the surface. An operator might post screenshots showing they're "buying along with you" — but in practice, they bought earlier, at a lower price, and are waiting for your money to push the price up before they exit. Warning signs include offers to share profits if you hand over account access, hints about "tomorrow's pick" designed to get you in early, and channels that charge tiered monthly fees (anything from a few thousand won to hundreds of thousands) for stock tips. If you've suffered losses through one of these schemes, the standard path in Korea is: file a complaint with the FSS (금감원 민원), assess the viability of a civil damages claim, and if the facts support it, file a criminal complaint (고소·고발). 4. If You Work at a Listed Company or Financial Firm Front-running isn't just a personal liability issue — it becomes a corporate governance failure the moment a senior employee is involved. For listed companies, a single suspicious trade by an executive can crater market trust and share price, and regulators have been clear that internal control systems will be scrutinized alongside the individual. Strengthened disclosure rules around insider transactions mean "we dealt with it internally" is no longer a viable response. For securities firms, asset managers, and other financial institutions, the exposure is higher because information access is higher. Analysts, PMs, traders, and sales staff are structurally positioned to know things before the market does — and that's precisely why the compliance burden is heavy. One enforcement action can trigger licensing risk, reputational damage, and regulatory scrutiny across the entire firm. 5. The Minimum Your Company Should Have in Place Whether you're a small listed company or a mid-sized asset manager, the logic of "we're too small to be a target" is exactly how firms end up making headlines. On internal policy, you need a written definition of material non-public information, clear procedures for how it's handled, mandatory account disclosure and trade reporting requirements for employees and related parties, and blackout periods around disclosure events. On training and attestation, key departments — finance, strategy, IR, research, sales — should receive regular compliance training. New hires and newly promoted staff should sign attestations acknowledging their obligations. On monitoring, periodic review of employee and related-party trading patterns, and sampling of trades around disclosure events, is the baseline. On incident response, you should have a documented procedure covering internal investigation authority, communication standards for dealing with the FSS, Korea Exchange, and prosecutors, and a protocol for board and audit committee reporting. If You've Been Affected — or Want to Get Ahead of the Risk For individual investors who suspect they've been the victim of a front-running scheme, we assess the facts and advise on the realistic options across criminal, civil, and regulatory channels. For listed companies and financial firms, we offer a structured review covering internal policy gaps, employee training design, and a full incident response manual — including FSS, Korea Exchange, and prosecutorial engagement. If a suspicious trade has already been flagged internally, we can advise from the investigation stage through to external response. You don't need to have everything figured out before reaching out. A brief initial consultation is enough to get a clear picture of where the risk sits.
-
Pharmaceutical Law Violations in Korea: What Pharma Companies & Distributors Must Review Now
Why You Need to Review Compliance Now Regulatory scrutiny over pharmaceutical rebate practices in Korea is intensifying. What is notable is that enforcement is no longer limited to individual misconduct but is increasingly focused on the overall transaction structure of a company. Authorities are examining how sales, contracts, and financial flows are designed and whether those structures, in substance, incentivize prescriptions or product adoption. Pharmaceutical companies and distributors operating in Korea are subject not only to the Pharmaceutical Affairs Act, but also to the Medical Service Act, national health insurance regulations, and fair trade laws. This layered regulatory framework creates a situation where a single transaction can raise multiple legal issues at once. In this environment, superficial compliance systems or loosely implemented internal controls can become a risk factor rather than a safeguard. If internal processes appear formal but lack substance, they may be interpreted as evidence of systematic or intentional violations. As a result, companies must move beyond field-level caution and instead reassess their entire structure, including contracts, expense allocation, and internal approval systems, from a regulatory perspective. Key Risk Areas for B2B Pharmaceutical Businesses One of the most common issues arises from rebate structures tied to prescription volume or product adoption. Even when benefits are provided under the label of marketing support, education, or promotional activities, they may still be treated as illegal rebates if there is a clear connection to sales performance. Another major risk involves consulting or marketing agreements that lack substantive deliverables. Payments made as advisory fees, research funding, or academic sponsorships may be questioned if there is no meaningful output such as reports, meeting records, or measurable contributions. In such cases, authorities may view the arrangement as a disguised incentive rather than a legitimate contract. Additionally, inflated or fictitious expenses present a significant exposure. Creating artificial costs through fabricated service contracts or exaggerated advertising fees to fund rebates can lead not only to pharmaceutical law violations but also to tax-related issues. These cases often trigger broader investigations that combine regulatory enforcement with financial scrutiny. Legal and Business Consequences Violations of Korean pharmaceutical regulations can lead to both criminal liability and administrative sanctions. In serious cases, executives and employees may face imprisonment or fines, and the company itself may also be penalized under joint liability provisions. Where misconduct is repeated or structurally embedded, enforcement trends indicate that actual custodial sentences are increasingly being considered. Administrative measures can have an even more immediate impact on business operations. These may include suspension of sales, significant monetary penalties, and reimbursement or clawback actions under national health insurance rules. Beyond formal sanctions, companies often experience secondary consequences such as loss of business partners, exclusion from procurement opportunities, and deterioration in financial credibility. In practice, these combined effects can threaten the long-term viability of the business. What Must Be Reviewed Immediately At this stage, companies should first examine whether their contract and expense structures are genuinely tied to real services and outcomes. Agreements labeled as consulting, services, or academic support must be supported by clear documentation and tangible deliverables. If such arrangements are directly or indirectly linked to prescription or sales performance, they are likely to be scrutinized as potential rebate schemes. It is equally important to review internal sales processes and approval systems. Companies need to ensure that promotional expenses and support payments are approved based on clear and consistent criteria, and that the decision-making process is fully traceable. If the approval structure cannot be explained or reconstructed, the organization itself may be exposed to allegations of intentional or negligent involvement. Finally, compliance frameworks must be practical and enforceable. Basic measures such as training sessions or written acknowledgments are no longer sufficient. Effective compliance requires integrating anti-rebate principles into KPI design, incentive structures, and ongoing monitoring systems. The ability to detect irregular transactions early and correct them internally is one of the most important factors in reducing regulatory risk. The Outcome Is Often Determined Before the Investigation Begins In many cases, the outcome of pharmaceutical compliance issues in Korea is effectively determined before a formal investigation is initiated. Once authorities conduct a search or begin an inquiry, they rely heavily on existing records, including contract structures, financial flows, and documented internal decisions. At that point, it becomes extremely difficult to modify or reframe the underlying structure. For this reason, proactive review and restructuring are critical. The key question is whether the company’s current transaction framework can withstand regulatory scrutiny from an objective third-party perspective. If there is any uncertainty, it is advisable to conduct a compliance review before the risk escalates into an investigation.
-
A Legal Guide by a Pseudo-Investment Advisory Lawyer
The Decisive Difference Between Pseudo-Investment Advisory Business and Investment Advisory Business Many operators run paid “signal groups” or trading rooms on platforms such as KakaoTalk or Telegram relying solely on a pseudo-investment advisory business registration. However, in actual legal assessments, the most critical issue is individualization. A pseudo-investment advisory business provides non-personalized, general investment information to an unspecified audience through publications, broadcasts, or online postings. In contrast, an investment advisory business offers customized advice tailored to a specific individual’s investment profile, which requires formal registration with the Financial Services Commission. Following the 2024 amendment to the Capital Markets Act, structures in which operators receive compensation and directly exchange opinions with users online are increasingly likely to be classified as investment advisory services. Accordingly, responding to member questions in paid groups by specifying particular stocks or precise buy/sell timing carries a high risk of being deemed unregistered investment advisory activity, subject to criminal penalties. Key Prohibited Practices Operators Must Avoid In investigations and disputes, the following conduct most frequently becomes problematic: First, providing individualized investment advice. The moment an operator gives a member a tailored instruction such as “Do not average down on this stock,” it may constitute a violation of the prohibition on unregistered investment advisory services. Second, guaranteeing profits or covering losses. Statements such as “principal guaranteed” or “fixed monthly returns of 5%” may themselves violate the Capital Markets Act and can result in up to three years’ imprisonment or fines of up to KRW 100 million. Third, false or exaggerated advertising. Posting fabricated profit screenshots, impersonating investors, or claiming superiority over competitors without objective evidence may escalate into fraud charges. Mandatory Compliance Measures and Internal Controls When operating signal groups or investment-information services, the following points must be clearly disclosed on websites, notices, and pinned messages: No one-to-one consultations or asset management services are provided Investment losses are possible and responsibility rests solely with the investor The operator is a registered pseudo-investment advisory business, not a licensed financial investment company In addition, pseudo-investment advisory registrations must be renewed every five years. Failure to complete mandatory education or having a prior violation of financial laws may result in rejection of the registration. For virtual asset (cryptocurrency) signal groups, the Virtual Asset User Protection Act applies. Engaging in insider trading, market manipulation, or unfair trading practices may lead to severe criminal penalties, including imprisonment of one year or more. In particular, pump-and-dump schemes involving coordination with specific projects are currently under intensive regulatory scrutiny. Why Legal Support from Decent Law Firm Matters Decent’s virtual asset and financial regulation team goes beyond simple registration assistance, providing comprehensive management of legal risks across the entire business structure. Formation and operational advisory We design service structures, terms of use, and advertising language to ensure compliance within the scope of pseudo-investment advisory regulations. Criminal investigation defense We respond to allegations of unregistered advisory services, fraud, or unfair trading by developing legal arguments focused on the absence of conspiracy and fraudulent intent. Civil dispute representation We handle investor damage claims by structuring defenses based on the validity of limitation-of-liability clauses and comparative negligence principles. In an evolving regulatory environment, compliance must begin before issues arise, not after enforcement actions commence. If you are concerned about legal risks related to operating a pseudo-investment advisory business or signal group, we recommend consulting with a specialized lawyer for a proactive legal review.
